Basit öğe kaydını göster

Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361.

dc.contributor.authorFradet, Yves
dc.contributor.authorLoriot, Yohann
dc.contributor.authorAlva, Ajjai Shivaram
dc.contributor.authorCsoszi, Tibor
dc.contributor.authorÖZGÜROĞLU, Mustafa
dc.contributor.authorMatsubara, Nobuaki
dc.contributor.authorGeczi, Lajos
dc.contributor.authorCheng, Susanna Y.
dc.contributor.authorOudard, Stephane
dc.contributor.authorVulsteke, Christof
dc.contributor.authorMorales-Barrera, Rafael
dc.contributor.authorFlechon, Aude
dc.contributor.authorGunduz, Seyda
dc.contributor.authorRodriguez-Vida, Alejo
dc.contributor.authorMamtani, Ronac
dc.contributor.authorYu, Evan Y.
dc.contributor.authorLiu Chih-Chin, Liu Chih-Chin
dc.contributor.authorImai, Kentaro
dc.contributor.authorMoreno, Blanca Homet
dc.contributor.authorPowles, Thomas
dc.date.accessioned2021-12-10T10:14:11Z
dc.date.available2021-12-10T10:14:11Z
dc.date.issued2021
dc.identifier.citationLoriot Y., Alva A. S. , Csoszi T., ÖZGÜROĞLU M., Matsubara N., Geczi L., Cheng S. Y. , Fradet Y., Oudard S., Vulsteke C., et al., "Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361.", JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.6, 2021
dc.identifier.issn0732-183X
dc.identifier.otherav_330254b4-b18d-479d-b479-33530c90e957
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/169488
dc.identifier.urihttps://doi.org/10.1200/jco.2021.39.6_suppl.435
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectOncology
dc.subjectHealth Sciences
dc.titlePost-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361.
dc.typeMakale
dc.relation.journalJOURNAL OF CLINICAL ONCOLOGY
dc.contributor.departmentUNICANCER , ,
dc.identifier.volume39
dc.identifier.issue6
dc.contributor.firstauthorID2615903


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster